 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registered public offering of 4,600,000 of its common shares, including 600,000 shares sold upon full exercise of the underwriters option to purchase additional shares, at a price to the public of 5.00 per share, primarily with institutional investors including several specialist biotech funds and certain existing shareholders. 